Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | LAP3 | P28838 | 2/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10074273 | 0.92 | CTSD (0.33) | RENCTSSTLR2 | |
| SCHEMBL10074152 | 0.87 | DPP4 (0.36) | RENCTSSDPP4DPP7 | |
| SCHEMBL10074129 | 0.87 | REN (0.37) | RENCTSSLAP3ANPEPRNPEP | |
| SCHEMBL10078267 | 0.87 | REN (0.37) | RENCTSSLAP3ANPEPRNPEP | |
| SCHEMBL10074716 | 0.87 | REN (0.37) | RENCTSSLAP3ANPEPRNPEP | |
| SCHEMBL6872783 | 0.87 | CTSD (0.34) | TLR2 | |
| SCHEMBL10074457 | 0.86 | DPP4 (0.41) | RENDPP4DPP7 | |
| SCHEMBL10074326 | 0.86 | DPP4 (0.41) | RENDPP4DPP7 | |
| SCHEMBL10078259 | 0.85 | SYK (0.37) | RENCTSSADRB2ADRB1ADRB3 | |
| SCHEMBL10074471 | 0.85 | SYK (0.37) | RENCTSSADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418196-A1 | Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors | IMTM GmbH (DE) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | IMTM GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028995-A1 | NOVEL COMPOUNDS FOR MEDICAL USE AS PEPTIDASE EFFECTORS | SERPINB1, CMA1, CPA3 | REN 449/4885CTSS 43/4885TLR2 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.